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Younger men had signiﬁcantly better mean UF, UB, and SF
domain scores one-year after RP than older men. Men < 55 years
old are more likely than older men to experience a severe decline
of sexual bother but trend toward a lower risk of a severe urinary
bother.
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OBJECTIVES: To compare the performance of a disease speciﬁc
satisfaction measure in overactive bladder (OAB-S) to the generic
Treatment Satisfaction Questionnaire for Medication (TSQM).
METHODS: The OAB-S consists of ﬁve scales (Expectations
with OAB control, Control, Impact on daily living with OAB,
Tolerability, and Satisfaction with OAB control) and ﬁve global
questions related to expectation and satisfaction. The TSQM
consists of four scales (Effectiveness, Convenience, Side effects
and Global satisfaction). The questionnaires were administered
to 134 subjects treated for their OAB with medication at base-
line and two weeks later. RESULTS: All scales on both ques-
tionnaires satisﬁed the minimum recommended level for internal
consistency reliability (Cronbach’s alpha >0.70). The test re-test
reliability of the all scales and individual items on the OAB-S
showed good reliability (ICC > 0.70; weighted Kappa >0.50);
however only the Global satisfaction domain of the TSQM
demonstrated good reliability (ICC = 0.82). The ability of the
questionnaires to discriminate among known groups of patients
based on subject-reported OAB symptoms severity was tested
and the relative validity (RV) was calculated. The RV was higher
for the OAB-S scores compared to the TSQM scores of same
content (e.g., TSQM Side effect RV = 0.08 vs OAB-S Tolerabil-
ity RV = 0.20). The effect sizes for the domains related to the
medication effectiveness were similar for both the TSQM and
OAB-S (TSQM Effectiveness ES = 0.26 vs. OAB Control ES =
0.25); however, the effect sizes for the other domains were higher
for the OAB-S compared to the TSQM indicating better respon-
siveness for the OAB-S. CONCLUSION: The OAB-S is better
able to discriminate patients based on their OAB severity level,
has better responsiveness to change and better reliability com-
pared to the TSQM. The TSQM is a good measure that is appro-
priate to assess satisfaction across different disease states, while
the OAB-S, a disease-speciﬁc measure of satisfaction, is prefer-
able in trials with patients with OAB.
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OBJECTIVE: Previous research has demonstrated that overac-
tive bladder (OAB) impacts 34 million people in the US and
results in $841 million in lost productivity per year. The objec-
tive of this study was to determine whether OAB patients receiv-
ing the transdermal oxybutynin patch experience productivity
improvements. METHODS: Data were obtained from partici-
pants in the Multicenter Assessment of Transdermal Therapy in
Overactive Bladder with Oxybutynin (MATRIX). Patients
enrolled in MATRIX received the oxybutynin patch 3.9mg/day
during this six-month, prospective, multicenter, US study. Self-
reported work productivity was captured at baseline, three and
six-months using the Work Productivity Questionnaire (WPQ),
an 8-question subset of the Work Limitations Questionnaire
(WLQ). The WPQ includes physical, mental (concentration),
time (interruptions and adherence to schedule) and output
(ability to handle workload) scales and a mean WPQ Index was
computed to estimate overall productivity loss. A productivity
loss score was computed to determine the percent reduction of
productivity in study participants compared to healthy individ-
uals. RESULTS: MATRIX enrolled 2878 patients (53.5%
working age [18–64]; 38.9% (n = 1112) employed) at 327 sites.
Of the working age population, 92% were female, 81% were
Caucasian, and the most common occupations noted were pro-
fessional (37%), manager/administrator (14.7%) and sales/retail
(10.4%). WPQ Index data was available for 740 patients at base-
line, 491 at month 3, and 408 at month 6. The mean (SD) WPQ
Index score was 8.2 (6.67) at baseline, and decreased signiﬁ-
cantly at 3-, and 6- months, to 5.8 (5.98), and 5.1 (5.58), respec-
tively (p < 0.0001). Improvements in productivity were observed
at 3- and 6-months across time, mental, physical and output
domains (p < 0.0001). Overall productivity loss decreased from
7.7% at baseline to 5.5% at month 3 and to 4.8% at month 6.
CONCLUSION: Transdermal oxybutynin results in improved
work productivity in patients with OAB.
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OBJECTIVES: This study uses conjoint analysis to examine clin-
ical factors that inﬂuence the decision to use speciﬁc IgE blood
testing as a diagnostic procedure for patients suspected of having
allergic rhinitis. METHODS: Participants included a random
sample of 50 family physicians in Alabama. For the conjoint
analysis physicians evaluated 11 patient proﬁles (repeated 
measures) containing four clinical factors: symptom severity,
symptom length, patient history, and medication use (prescribed
antihistamines, nasal spray, over-the-counter medications). Deci-
sions to test or not test were elicited as dichotomous responses.
Visual analog scales were used to support study validity.
RESULTS: The largest coefﬁcients were obtained for symptom
severity (medium = 2.86; high = 5.12) and symptom length
(medium = 1.04; high = 1.03) with history and medication use
having moderate inﬂuence in the decision process. The overall
conditional logistic model was signiﬁcant (X2 = 194.8, P <
0.001). All physicians sampled valued testing compared to not
testing. For older physicians (age > 50) perceived value compared
to not testing was signiﬁcantly higher (P < 0.05). CONCLU-
SIONS: The value of speciﬁc IgE testing is strongly linked to how
well test results relate to symptoms (severity, length). Family
physicians perceive that speciﬁc IgE blood testing is valuable to
their practice.
